Anti-BRCA2 antibody (Agarose) (ab1292)


  • Product nameAnti-BRCA2 antibody (Agarose)
    See all BRCA2 primary antibodies
  • Description
    Rabbit polyclonal to BRCA2 (Agarose)
  • ConjugationAgarose
  • Tested applicationsSuitable for: IPmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide (Human) conjugated to KLH - which represented a portion of human Breast Cancer Gene 2 encoded within exon 27 (LocusLink ID 675).

  • General notes

    Affinity purified antibodies were coupled to agarose beads using a cyanogen bromide method.



Our Abpromise guarantee covers the use of ab1292 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesImmunoprecipitation: Use at 15 to 25 µl of gel slurry per 0.1 to 1 mg of protein lysate or extract.
  • Target

    • FunctionInvolved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures.
    • Tissue specificityHighest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen.
    • Involvement in diseaseDefects in BRCA2 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
      Defects in BRCA2 are the cause of pancreatic cancer type 2 (PNCA2) [MIM:613347]. It is a malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.
      Defects in BRCA2 are a cause of susceptibility to breast-ovarian cancer familial type 2 (BROVCA2) [MIM:612555]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate.
      Defects in BRCA2 are the cause of Fanconi anemia complementation group D type 1 (FANCD1) [MIM:605724]. It is a disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.
      Defects in BRCA2 are a cause of glioma type 3 (GLM3) [MIM:613029]. Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.
    • Sequence similaritiesContains 8 BRCA2 repeats.
    • Post-translational
      Phosphorylated by ATM upon irradiation-induced DNA damage.
      Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation. In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation.
    • Information by UniProt
    • Database links
    • Alternative names
      • BRCA 2 antibody
      • BRCA1/BRCA2 containing complex subunit 2 antibody
      • Brca2 antibody
      • BRCA2_HUMAN antibody
      • BRCC 2 antibody
      • BRCC2 antibody
      • Breast and ovarian cancer susceptibility gene early onset antibody
      • Breast cancer 2 early onset antibody
      • Breast Cancer 2 tumor suppressor antibody
      • Breast cancer susceptibility protein BRCA2 antibody
      • Breast cancer type 2 susceptibility protein antibody
      • BROVCA2 antibody
      • FACD antibody
      • FAD 1 antibody
      • FAD antibody
      • FAD1 antibody
      • FANCB antibody
      • FANCD 1 antibody
      • FANCD antibody
      • FANCD1 antibody
      • Fanconi anemia complementation group D1 antibody
      • Fanconi anemia group D1 protein antibody
      • GLM3 antibody
      • OTTHUMP00000018803 antibody
      • OTTHUMP00000042401 antibody
      see all

    References for Anti-BRCA2 antibody (Agarose) (ab1292)

    ab1292 has not yet been referenced specifically in any publications.

    Product Wall

    Thank you for your enquiry and your interest in our products. We would like to confirm that the two product are the same and from the same originator. The only difference is that ab1292 is Rabbit polyclonal to BRCA2 (Agarose) suitable for only IP ap...

    Read More